Search clinical trials for: SACUBITRIL - VALSARTAN

Total 501 results

Novartis

Completed

Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension
Novartis Pharmaceuticals

Completed

Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day

Hypertension

France, Tunisia
Novartis Pharmaceuticals

Completed

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

Hypertension

United States, Hungary, Poland, Turkey, Belgium, France, Germany, India, Italy, Slovakia, Sweden
Novartis

Completed

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension; Hypertrophy, Left Ventricular

Germany
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
Novartis

Completed

Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension

Hypertension

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension

Hypertension

China
Takeda

Completed

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

United States, Mexico, Peru, Brazil, Argentina, Puerto Rico
Novartis
The TIMI Study Group

Completed

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Myocardial Ischemia | Post Acute Coronary Syndrome

Germany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Hypertension

United States
Novartis Pharmaceuticals

Completed

Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg (EXPLOR)

Hypertension

France
Novartis

Completed

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT)

Stage 2 Systolic Hypertension

United States
LG Life Sciences

Completed

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Novartis

Completed

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

De Novo Renal Transplantation
Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
Novartis

Completed

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Hypertension

India
University Hospital, Grenoble

Completed

Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients (VALSAS)

Obstructive Sleep Apnea | Hypertension,

France
Sanofi

Completed

Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension (COSIMA2)

Hypertension

India, Malaysia, Philippines, Singapore, Taiwan, Tunisia, Egypt, Korea, Republic of, Hong Kong, Indonesia, Morocco, Pakistan, Thailand, Vietnam
Kagoshima University

Unknown

Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) (KACT)

Hypertension | Obesity

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers

Healthy | Pharmacokinetics of Valsartan

Japan
Nanjing University School of Medicine

Completed

To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

Membranous Nephropathy

China
Nanjing University School of Medicine

Completed

To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)

Diabetic Nephropathy

China
HeartDrug Research LLC
Novartis

Unknown

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

Diabetes Mellitus

United States
Charite University, Berlin, Germany
University of Ulm

Completed

Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus

Coronary Artery Disease | Hypertension | Type 2 Diabetes Mellitus

Germany
Gulhane School of Medicine

Completed

The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension

Hypertension | Diabetes | Proteinuria

Turkey
University of Aarhus
Novartis; Danish Heart Foundation; Danish Cardiovascular Research Academy

Terminated

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Hypertension | Microvascular Angina

Denmark
University of Vigo
Hospital Clinico Universitario de Santiago; Xunta de Galicia; Ministerio de Educacion...

Completed

Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy (MAPEC)

Hypertension

Spain
Gruppo di Ricerca GISSI

Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Atrial Fibrillation

Italy, Switzerland
Samsung Medical Center

Unknown

The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

Proteinuria | Chronic Kidney Disease

Korea, Republic of
Nantes University Hospital

Terminated

Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Heavy Proteinuria

France
Federico II University

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage

Hypertension | Ventricular Remodeling | Erectile Dysfunctions

Italy
University of Vigo
Novartis; Hospital Clinico Universitario de Santiago

Completed

Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose

Hypertension

Spain
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Assistance Publique - Hôpitaux de Paris

Completed

Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker

Healthy

France
Novartis

Completed

Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients

Hypertension

Taiwan
Intermountain Health Care, Inc.
Novartis

Terminated

The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

Atrial Fibrillation

United States
Assaf-Harofeh Medical Center

Unknown

Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

Hypertension
University of Pavia

Unknown

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

Essential Hypertension

Italy
Novartis

Completed

Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension

Hypertension

Brazil
Novartis

Completed

Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months

Hypertension

Singapore
Kitasato University
Yokohama City University Medical Center; St. Marianna University School of... and other collaborators

Unknown

Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension

Hypertension | Type 2 Diabetes Mellitus

Japan
Saitama Medical University

Completed

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Cardiovascular Disease
Novartis

Completed

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

Healthy

United States
Novartis

Completed

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

Healthy

United States
Novartis

Completed

To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers

Healthy

India
Hospital Britanico

Completed

Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy

IGA Nephropathy

Argentina
Shiga University

Unknown

Rationale and Design for Shiga Microalbuminuria Reduction Trial

Hypertension | Diabetes Mellitus | Albuminuria

Japan
Jikei University School of Medicine

Unknown

A Morbidity-Mortality and Remodeling Study With Valsartan

Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan

3

Subscribe